IRVINE, California., June 20, 2024 — Hiperwall, Inc., a leader in software-defined, IP-based video wall and signage control solutions, today announced the release of Hiperwall Version 9.0, a significant milestone in the evolution of its AV-over-IP video wall technology. With a focus on delivering unparalleled performance, flexibility, and ease of use, Hiperwall 9.0 introduces several innovative features designed to meet the diverse and mission-critical needs of command-and-control room customers.
“Taking into consideration the feedback we’ve received from customers, integrators, and channel partners, we made Hiperwall 9.0 an even more powerful tool for streamlining command and control room workflows and operations,” said Dr. Stephen Jenks, co-founder and CEO.
Empowering Command and Control Rooms
At the heart of Hiperwall 9.0 lies a suite of user experience enhancements aimed at revolutionizing command and control room operations. Among the key features is the introduction of Text Labels and Content Borders, allowing operators and administrators to add text labels to content items and utilize unique color borders for enhanced visual impact of shared objects.
Labels: Users can now assign unique text labels to content items through HiperController, HiperOperator, or HiperInterface (Hiperwall’s XML- and HTTP-based control interface), providing a distinct identification method in content lists and improving search functionality. When displayed on the video wall, labels aid in content identification for viewers in the room, supporting multiple languages and character sets.
Borders: The introduction of borders allows users to draw attention to specific content on the video wall. Users can choose the border color and thickness, providing a dynamic and attention-grabbing visual experience.
For customers with multiple video walls, text labels and content borders can be adjusted and customized to compensate for wall sizes, viewing distances, and customer preferences, ensuring the best viewing experience.
Unlimited Video Wall Layout Flexibility
With Hiperwall 9.0, all video wall systems will now benefit from the enhanced video wall layout flexibility of HiperLayout. Historically an add-on option for higher-end systems, the inclusion of HiperLayout in all Version 9 systems makes it possible for customers to group displays into walls and allows centralized control and content sharing across multiple video walls managed by a single HiperController PC. This upgrade provides numerous other benefits, including the ability to define unique SmartSnap® grids for each video wall in the system, incorporate displays of different sizes and resolutions seamlessly, use arbitrary display names, and easily rotate displays at any angle for artistic layouts.
Enhanced User Experience
The latest version of HiperOperator, the main control application for in-room and remote video wall operators, builds upon the significant UI overhaul of Version 8.5 and introduces various new features to enhance ease of use. These features include drag-and-drop functionality for seamless content movement, extended SmartSnap® and SmartSwap® capabilities, and the addition of labels and borders. Users can easily assign labels and custom borders within HiperOperator, streamlining content organization in command-and-control room workflows.
HiperSource Sender also received a significant overhaul aimed at simplifying source management and offering users a comprehensive view of all created sources within the application window, including crucial information such as connection status, size, UUID, and name. The redesigned UI facilitates easy screen area capture through a drag-and-drop sizer window, streamlines the process of adding new sources by opening a dedicated configuration window, and enhances privacy by graying out Sender sources during sensitive activities. It also now offers expanded support for systems with displays of different resolutions and is particularly beneficial for systems utilizing 4K UHD displays in multi-display setups. Beyond the new UI and extended display support, HiperSource Sender now alerts users when configurations pose technical challenges, notifying users with a warning and offering suggestions on how to resolve it.
Quick Recovery with Settings Backup
Exclusive to HiperCare customers, Hiperwall Version 9.0 introduces Settings Backup, a new feature that allows system administrators to save and restore their video wall settings easily. This ensures quick recovery following hardware replacements or upgrades and facilitates the migration of video wall systems to new sites. Additionally, it simplifies the setup of new Hiperwall video wall sites with settings that match previous installations. With Settings Backup, system administrators can efficiently manage and recover Hiperwall settings, ensuring seamless control and recovery of system components in critical situations.
How to Get Hiperwall Version 9.0 Software
Hiperwall version 9.0 control room video wall software can be purchased today through authorized dealers. Customers with an active HiperCare contract are eligible to upgrade their systems for free. Customers without HiperCare who want to upgrade to version 9.0 are encouraged to contact their authorized Hiperwall dealer or contact Hiperwall to learn more.
For more information about Hiperwall video wall control software, please visit www.hiperwall.com. To see if Hiperwall software is right for your organization’s video wall, please request a sales consultation at https://www.hiperwall.com/contact_us.
IRVINE, Calif., June 4, 2024 –TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the formation of its new commercial leadership team, dedicated to driving the company’s expansion across the Americas, APAC (Asia-Pacific) and EMEAI (Europe, Middle East, Africa, and India). With extensive experience and expertise with their respective markets, each member of this team will serve as the general manager for their region. With a focused goal of expanding the company’s global footprint, the commercial leadership team is poised to enhance market reach, foster strategic partnerships, and ultimately expand the number of Alphabeam BNCT installations at clinical sites worldwide.
TAE Life Sciences’ commercial leadership team members:
Anna Theriault, GM for the Americas, and Global VP of Marketing: A tenured radiation oncology business and marketing executive, Anna brings a wealth of experience in driving adoption in evolving radiation therapy, data, and oncology solutions from previous senior leadership roles at Accuray and Elekta.
Michael Sandhu, GM for Europe, the Middle East, Africa, and India: With over 30 years of experience in radiation therapy, Michael founded remediumRT AG and held key roles at Varian Medical Systems. He specializes in emerging market growth and government negotiations.
Peter Stafford, GM for Asia Pacific: With over 15 years of experience in radiation oncology and biopharmaceuticals, Peter has held key technical and business roles at Accuray and Pharmaceutical Product Development, Inc.
In a strategic move to bolster its presence in India, TAE Life Sciences is excited to announce Radiosurgery Global (RSG) as its new distribution partner for the country. RSG excels in providing comprehensive support through a network of skilled consultants, partners, and advisors specializing in sales channels, project management, construction, digital and print marketing, investment advisory, engineering, service, and financing.
“TAE Life Sciences’ innovative Alphabeam BNCT system has the potential to revolutionize cancer care with its unparalleled treatment accuracy. We are excited to combine their cutting-edge solutions with our established radiation oncology distribution infrastructure and sales network to advance the field of radiation oncology in India,” said Kapil Kalra, Managing Director, Radiosurgery Global.
Working with RSG will help TAE Life Sciences to strategically target both seasoned professionals in radiation oncology as well as the institutions adopting the latest cancer care innovations in India. With RSG’s proven expertise and extensive experience, this partnership is set to significantly enhance TAE Life Sciences’ reach and growth in a key market.
“At TAE Life Sciences, our mission is to make transformative advancements in cancer treatment accessible worldwide. The appointment of our new commercial leadership team and expansion of our distribution partners are pivotal steps toward realizing this vision,” said Rob Hill, CEO, TAE Life Sciences.
For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit www.taelifesciences.com.
Irvine, CA – June 4, 2024 –Cell Therapy Tools (CTT), a pioneering biotechnology company dedi
cated to advancing the use of cell-based therapeutics in modern medicine, today announced that it is now enrolling canine patients suffering from Osteoarthritis (OA) into a clinical study utilizing its investigational cell therapy called Chondroshield®.
Conducted in accordance with United States Food and Drug Administration (FDA) regulations, CTT is poised to embark on a significant clinical investigation targeting OA in canines, a debilitating condition that affects the joints of many dogs. The study, slated to commence in the state of Washington, will be overseen by Dr. Robert “Jeff” Mayo, a distinguished small animal orthopedic surgeon and Chief Veterinary Medical Officer at CTT.
“Initial clinical applications of Chondroshield have shown dogs to respond well to the therapy,” Mayo commented. “To date, there have been no reported side effects, and all patients were able to discontinue interventional pain control after receiving the therapy.”
“Through rigorous laboratory testing, our patented allogeneic platelet lysate therapy, serving as the foundation for Chondroshield, has not only the potential to alleviate pain and inflammation, but also the potential to actively stimulate joint restoration,” Dr. Fari Izadyar, founder and CEO of CTT, stated.
Chondroshield marks a potentially significant leap forward in Canine Osteoarthritis (OA) treatment. Chondroshield utilizes the cytokines and growth factors found within platelets to stimulate both an anti-inflammatory and healing response within the affected joint. While autologous platelet rich plasma (PRP) is a well-established therapy, its production is labor-intensive, requires blood collection from the patient in order to create it, and is not produced to strict standards for consistency. Chondroshield is an allogeneic pooled platelet lysate product, that if approved by the FDA, could serve as an off-the-shelf cell therapy that requires no blood collection from patients. This unique formulation contains growth factors and cytokines crucial for reducing inflammation and healing damage caused by OA. Recent lab studies have shown that Chondroshield enhances the proliferation and matrix production of canine chondrocytes, vital for cartilage repair.
Collaborating closely with Maven, a prominent company specializing in pet activity monitoring solutions, CTT will leverage cutting-edge AI technology to enhance the diagnosis and monitoring of OA in dogs. Maven’s expertise in activity monitoring will complement the clinical study by providing valuable insights into treatment progress and efficacy.
Dr. Izadyar continued, “We are dedicated to proving the therapeutic value of Chondroshield in a clinical setting, as well as to providing hope to the many dogs enduring the challenges of this debilitating inflammatory disease, alongside their owners.”
The Chondroshield clinical study is currently in the enrollment phase, welcoming participation from pet owners whose dogs have been diagnosed with Osteoarthritis. Pet owners interested in learning more about the trial are encouraged to contact CTT at https://celltherapytools.com/contact-us, or call 949-630-2050.
For media inquiries or additional information about Chondroshield and its potential clinical advantages, please contact ctt@wearenewera.com.
About Cell Therapy Tools
Cell Therapy Tools (CTT) is a clinical biotech firm focused on developing off-the-shelf allogeneic cell-based therapies for inflammatory and immune-mediated ailments. Founded in 2017 by dedicated veterinary professionals with extensive experience in cell therapy, regenerative medicine and platelet activation with low-level laser technology, CTT is engaged in the development of various therapies that reduce inflammation and empower the healing process. CTT’s objective is to enhance the body’s inherent healing capacities, ultimately improving patient care and well-being. Continuously expanding its product pipeline, the company is committed to obtaining FDA approval for its therapeutic innovations.
